Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · IEX Real-Time Price · USD
4.590
-0.190 (-3.97%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Achieve Life Sciences, Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | John A. Bencich M.B.A. |
Contact Details
Address: 22722 29th Dr. Se, Suite 100 Seattle, Washington 98021 United States | |
| Phone | 425-686-1500 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| John A. Bencich M.B.A. | Chief Executive Officer and Director |
| Dr. Richard A. B. Stewart | Executive Chairman |
| Dr. Cindy Jacobs M.D., Ph.D. | President, Chief Medical Officer and Director |
| Jerry Wan | Principal Accounting Officer |
| Dr. Anthony Clarke | Chief Scientific Officer |
| Jaime Xinos | Executive Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 6, 2024 | EFFECT | Notice of Effectiveness |
| May 2, 2024 | UPLOAD | Filing |
| Apr 26, 2024 | S-3 | Registration statement under Securities Act of 1933 |